Wedbush Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $25.00

Travere Therapeutics (NASDAQ:TVTX) had its price target increased by Wedbush from $17.00 to $25.00 in a research report released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Travere Therapeutics’ Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.03 EPS, FY2026 earnings at $2.81 EPS, FY2027 earnings at $3.83 EPS and FY2028 earnings at $3.92 EPS.

A number of other equities analysts also recently issued reports on the company. Leerink Partners reaffirmed an outperform rating and set a $20.00 price target on shares of Travere Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reduced their price target on Travere Therapeutics from $23.00 to $18.00 and set a buy rating on the stock in a research report on Friday, September 27th. Canaccord Genuity Group dropped their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a buy rating on the stock in a report on Monday, September 30th. Guggenheim dropped their price objective on shares of Travere Therapeutics from $25.00 to $23.00 and set a buy rating on the stock in a report on Friday, September 27th. Finally, Citigroup dropped their price objective on shares of Travere Therapeutics from $23.00 to $19.00 and set a buy rating on the stock in a report on Friday, September 27th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $19.75.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $16.41 on Wednesday. The firm has a 50 day moving average of $11.78 and a 200 day moving average of $8.97. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -8.73 and a beta of 0.73. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $18.60.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The business had revenue of $54.12 million for the quarter, compared to analyst estimates of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. On average, sell-side analysts predict that Travere Therapeutics will post -3.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now directly owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now directly owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jula Inrig sold 2,191 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $25,240.32. Following the completion of the sale, the insider now directly owns 62,633 shares in the company, valued at approximately $721,532.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,707 shares of company stock valued at $1,504,312. 3.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its stake in shares of Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock worth $18,200,000 after acquiring an additional 1,995,419 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Travere Therapeutics by 76.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock worth $9,159,000 after acquiring an additional 441,318 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Travere Therapeutics by 79.2% during the 1st quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock worth $1,423,000 after acquiring an additional 81,611 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Travere Therapeutics during the 1st quarter worth about $452,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Travere Therapeutics during the 4th quarter worth about $5,711,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.